Trial
NCT00263042
Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
—
Condition
Cardiovascular Disease
Intervention
Rimonabant
Why stopped
Company decision taken in light of demands by certain national health authorities
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-05-20